• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by 2seventy bio Inc.

    11/6/24 4:06:39 PM ET
    $TSVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TSVT alert in real time by email
    SC 13G/A 1 2seventybioTSVT.txt MS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* 2seventy bio, Inc. ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 901384107 ----------------------------------------------------- (CUSIP Number) September 30, 2024 ----------------------------------------------------- (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No.901384107 13G Page 2 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley I.R.S. # 36-3145972 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 2,712,448 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 2,813,087 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 2,813,087 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 5.5% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: HC, CO -------------------------------------------------------------------------------- CUSIP No.901384107 13G Page 3 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley & Co. LLC I.R.S. # 13-2655998 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 673,425 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 673,425 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 673,425 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 1.3% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: BD, CO -------------------------------------------------------------------------------- CUSIP No.901384107 13G Page 4 of 8 Pages -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: 2seventy bio, Inc. -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 60 BINNEY STREET CAMBRIDGE MA 02210 UNITED STATES OF AMERICA -------------------------------------------------------------- Item 2. (a) Name of Person Filing: (1) Morgan Stanley (2) Morgan Stanley & Co. LLC -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: (1) 1585 Broadway, New York, NY 10036 (2) 1585 Broadway, New York, NY 10036 -------------------------------------------------------------- (c) Citizenship: (1) Delaware. (2) Delaware. -------------------------------------------------------------- (d) Title of Class of Securities: Common Stock -------------------------------------------------------------- (e) CUSIP Number: 901384107 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [x] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with Sections 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with sections 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with sections 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No.901384107 13G Page 5 of 8 Pages -------------------------------------------------------------------------------- Item 4. Ownership as of September 30, 2024.* (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b) Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. (1) As of the date hereof, Morgan Stanley & Co. LLC has ceased to be the beneficial owner of more than five percent of the class of securities. Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit 99.2 Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (1) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release. CUSIP No.901384107 13G Page 6 of 8 Pages -------------------------------------------------------------------------------- Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 06, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley -------------------------------------------------------------------- MORGAN STANLEY Date: November 06, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley & Co. LLC -------------------------------------------------------------------- Morgan Stanley & Co. LLC EXHIBIT NO. EXHIBITS PAGE ----------- ---------- ---- 99.1 Joint Filing Agreement 7 99.2 Item 7 Information 8 * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.901384107 13G Page 7 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT --------------------------------------------------- November 06, 2024 --------------------------------------------------- MORGAN STANLEY and Morgan Stanley & Co. LLC hereby agree that, unless differentiated, this Schedule 13G is filed on behalf of each of the parties. MORGAN STANLEY BY: /s/ Christopher O'Hara --------------------------------------------------------------------- Christopher O'Hara/Authorized Signatory, Morgan Stanley Morgan Stanley & Co. LLC BY: /s/ Christopher O'Hara --------------------------------------------------------------------- Christopher O'Hara/Authorized Signatory, Morgan Stanley & Co. LLC * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.901384107 13G Page 8 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.2 ------------------ ITEM 7 INFORMATION The securities being reported on by Morgan Stanley as a parent holding company are owned, or may be deemed to be beneficially owned, by Morgan Stanley & Co. LLC, a wholly-owned subsidiary of Morgan Stanley.
    Get the next $TSVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TSVT

    DatePrice TargetRatingAnalyst
    6/6/2024$5.00 → $2.00Neutral → Sell
    Goldman
    1/31/2024Outperform → Market Perform
    TD Cowen
    1/31/2024$5.00 → $18.00Market Perform → Outperform
    Leerink Partners
    10/30/2023$6.00Outperform → Market Perform
    Leerink Partners
    10/12/2023$13.00Buy
    Citigroup
    9/13/2023$5.00Buy → Neutral
    Goldman
    9/12/2023Buy → Neutral
    Guggenheim
    7/28/2023$25.00 → $13.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TSVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 2seventy bio Inc.

      SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)

      11/6/24 4:06:39 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 2seventy bio Inc. (Amendment)

      SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)

      2/14/24 4:58:16 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 2seventy bio Inc. (Amendment)

      SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)

      2/14/24 4:21:54 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Casdin Capital, Llc bought $203,992 worth of shares (40,000 units at $5.10) (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/28/24 8:29:09 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Casdin Capital, Llc bought $3,899,050 worth of shares (777,377 units at $5.02) (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/25/24 9:44:59 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Leadership Updates

    Live Leadership Updates

    See more
    • 2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

      2seventy bio, Inc. (NASDAQ:TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the "Board"), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. "We are pleased to welcome Eli and Charlie to the 2seventy Board," said Dan Lynch, chair of the Board of Directors. "Eli is a highly regarded, leading life sciences and healthcare investor and has a deep understanding of and history with the Company. Charlie has a track record of helping compan

      3/20/24 5:04:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value

      Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh

      12/6/23 8:00:00 AM ET
      $BLUE
      $TSVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Deep Genomics Announces the Appointment of Brian O'Callaghan as CEO

      O'Callaghan, a well-regarded life-science business leader with global experience and a significant track record of success, joins as part of plan to evolve Deep Genomics as a forward-integrated biopharmaceutical company Founder and current CEO Brendan Frey, Ph.D., F.R.S.C. to assume new role of chief innovation officer, remain a member of the board and bolster plans for further technology development and innovation, leveraging artificial intelligence (AI) to decode RNA biology for novel drug development Lead independent director Chip Baird appointed as chair of the board Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines

      9/15/23 7:00:00 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Snow Jessica sold $11,364 worth of shares (2,298 units at $4.95), decreasing direct ownership by 0.90% to 254,193 units (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/19/25 4:49:01 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Baird William D Iii sold $25,180 worth of shares (5,092 units at $4.95), decreasing direct ownership by 0.45% to 1,121,034 units (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/19/25 4:48:27 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Eatwell Victoria sold $12,817 worth of shares (2,592 units at $4.95), decreasing direct ownership by 0.58% to 444,387 units (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/19/25 4:48:17 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    SEC Filings

    See more
    • SEC Form 10-Q filed by 2seventy bio Inc.

      10-Q - 2seventy bio, Inc. (0001860782) (Filer)

      5/7/25 4:16:20 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - 2seventy bio, Inc. (0001860782) (Filer)

      5/7/25 4:12:38 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.

      SC TO-T/A - 2seventy bio, Inc. (0001860782) (Subject)

      5/6/25 7:57:30 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

      Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas

      5/7/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

      Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure a

      3/25/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

      $5.00 per share, all-cash transaction Expected to close in the second quarter of 2025, subject to customary closing conditions 2seventy bio, Inc. (NASDAQ:TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE:BMY) ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025. "A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living wi

      3/10/25 10:17:00 PM ET
      $BMY
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Financials

    Live finance-specific insights

    See more
    • 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

      Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas

      5/7/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

      Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure a

      3/25/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

      Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in anticipated cost savings over the next several years 24% reduction in operating expenses versus the second quarter reflects continued progress on streamlining 2seventy's cost structure; third quarter net loss of approximately $10 million Ended quarter with approximately $192 million in cash, cash equivalents, and marketable securities; expected cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for

      11/12/24 7:00:00 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • 2seventy bio downgraded by Goldman with a new price target

      Goldman downgraded 2seventy bio from Neutral to Sell and set a new price target of $2.00 from $5.00 previously

      6/6/24 7:21:43 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio downgraded by TD Cowen

      TD Cowen downgraded 2seventy bio from Outperform to Market Perform

      1/31/24 9:14:22 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded 2seventy bio from Market Perform to Outperform and set a new price target of $18.00 from $5.00 previously

      1/31/24 7:24:00 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care